Cutera, Inc. Appoints Brent Hauser as President, International

$CUTR
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $CUTR alert in real time by email

Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe

Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023.

Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aesthetics industry experience in markets across the globe. Mr. Hauser and his family will be relocating to Australia in early 2024. Until that time, Mr. Hauser will work closely with the North American commercial leadership team to plan for and execute on a redesigned business model and go-to-market approach for AviClear in North America, both for existing and new customers.

Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Brent to the Cutera team. During his two decades in the aesthetics industry, Brent has demonstrated tremendous leadership capability and commercial savvy in markets across the globe. And in our time working together at Zeltiq, I developed tremendous respect for Brent as an individual, one who demonstrates all of the leadership commitments and core values to which Cutera aspires, including a relentless focus on our customers. I look forward to his contributions as we seek to grow our international business and optimize the launch of AviClear both in North America and abroad."

Mr. Hauser said, "We have a significant opportunity ahead of us at Cutera, as we seek to expand our presence in international markets and bring the exciting AviClear technology to customers outside of North America. I am honored to join and lead the international team, and to work with them to provide unmatched products and service to our customers."

About Brent Hauser:

Mr. Hauser has over two decades of aesthetics industry experience in commercial roles of increasing responsibility. Mr. Hauser started his career in the laser aesthetics industry at Solta Medical, where he held sales leadership positions in both the European and Asia Pacific regions. Subsequently, Mr. Hauser joined Zeltiq, where he rose to the position of President, North American Operations, responsible for all commercial activity in North America. Following the acquisition of Zeltiq by Allergan, Mr. Hauser became Vice President of Sales and Marketing for the CoolSculpting brand on a global basis. For the last two years, Mr. Hauser has served as Senior Vice President of Global Sales for InBrace. Mr. Hauser holds a Bachelor's Degree in Biology from Stanford University, where he was an All-American cross country runner, holding several school records. He currently serves on the board of directors of the Cure JM (juvenile myositis) Foundation.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.

Get the next $CUTR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CUTR

DatePrice TargetRatingAnalyst
3/22/2024Underperform → Mkt Perform
William Blair
7/27/2023$14.00 → $18.00Underweight → Neutral
Piper Sandler
5/11/2023Outperform → Mkt Perform
William Blair
5/10/2023$14.00Underweight
Piper Sandler
3/30/2023Buy → Hold
Maxim Group
1/31/2023Mkt Perform
William Blair
1/11/2023$85.00 → $33.00Overweight → Neutral
Cantor Fitzgerald
12/28/2022$78.00 → $68.00Overweight
Stephens
More analyst ratings

$CUTR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cutera Announces Voluntarily Delisting from Nasdaq

    Cutera, Inc. ("Cutera" or the "Company") (NASDAQ:CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC ("Nasdaq") of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be effective on or about March 30, 2025. Following such delisting, the Company intends to file a Form 15 with the SEC to indefinitely suspend the Company's reporting obligations under the Securities Exchange Act of 1934, as amended. The s

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Cutera Takes Steps to Strengthen Financial Foundation and Position the Company for Long-Term Success

    Enters into agreement to reduce debt by nearly $400 million and raise $65 million of new money from existing lenders Implementing pre-packaged financial restructuring plan with strong support of lenders, expected to emerge expeditiously within 60 days Continues to operate as usual and provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term s

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Cutera® Announces Partnership with the Adaptive Training Foundation

    Cutera collaborates with Dr. Edward Alvarez to provide truFlex® muscle stimulation treatments to help enhance the strength and endurance of adaptive athletes CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announces their partnership with the Adaptive Training Foundation (ATF), a non-profit organization that provides access and inclusion to individuals living with physical or traumatic impairments empowering them through exercise and community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112062983/en/Cutera, Dr. Edward Alvarez, and the Adaptive Training team at the ATF facility in D

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$CUTR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CUTR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CUTR
SEC Filings

See more

$CUTR
Leadership Updates

Live Leadership Updates

See more
  • Cutera® Appoints Jeryl L. Hilleman to Board of Directors

    Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Cutera Appoints Stephana Patton as Chief Legal Officer

    Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

    $CUTR
    $EIGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Cutera, Inc. Appoints Brent Hauser as President, International

    Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023. Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aest

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$CUTR
Financials

Live finance-specific insights

See more
  • Cutera® Announces Third Quarter 2024 Financial Results

    CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Cutera® to Announce Third Quarter Results on November 7, 2024

    Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Cutera® Announces Second Quarter 2024 Financial Results

    CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al

    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$CUTR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more